[
    "t in a mixture of 25 mM HEPES (pH 7.5), 10 mM MgCl<sub>2</sub>, and 1 mM DTT. Final substrate concentrations were 50 \u03bcM [\u03b3-33P]ATP (136mCi 33P ATP/mmol ATP, Amersham Pharmacia Biotech/Sigma Chemicals) and 10 \u03bcM peptide (SAM68 protein A332-443). Assays were carried out at 25\u00b0 C. in the presence of 15 nM Plk1 (A20-K338). An assay stock buffer solution was prepared containing all of the reagents listed above, with the exception of ATP and the test compound of interest. 30 \u03bcL of the stock solution was placed in a 96 well plate followed by addition of 2 \u03bcL of DMSO stock containing serial dilutions of the test compound (typically starting from a final concentration of 10 \u03bcM with 2-fold serial dilutions) in duplicate (final DMSO concentration 5%). The plate was pre-incubated for 10 minutes at 25\u00b0 C. and the reaction initiated by addition of 8 \u03bcL [\u03b3-33P]ATP (final concentration 50 \u03bcM).</p>The reaction was stopped after 60 minutes by the addition of 100 \u03bcL 0.14M phosphoric acid. A multiscreen phosphocellulose filter 96-well plate (Millipore, Cat no. MAPHN0B50) was pretreated with 100 \u03bcL 0.2M phosphoric acid prior to the addition of 125 \u03bcL of the stopped assay mixture. The plate was washed with 4\u00d7200 \u03bcL 0.2M phosphoric acid. After drying, 100 \u03bcL Optiphase \u2018SuperMix\u2019 liquid scintillation cocktail (Perkin Elmer) was added to the well prior to scintillation counting (1450 Microbeta Liquid Scintillation Counter, Wallac).</p>After removing mean background values for all of the data points, Ki(app) data were calculated from non-linear regression analysis of the initial rate data using the Prism software package (GraphPad Prism version 3.0cx for Macintosh, GraphPad Software, San Diego Calif., USA).</p>Plk1 Inhibition Assay:</p>Compounds were screened for their ability to inhibit Plk1 using a radioactive-phosphate incorporation assay. Assays were carried out in a mixture of 25 mM HEPES (pH 7.5), 10 mM MgCl<sub>2</sub>, 0.1% BSA, and 2 mM DTT. Final substrate concentrations were 100 \u03bcM [\u03b3-33P]ATP (115mCi 33P ATP/mmol ATP, Amersham Pharmacia Biotech/Sigma Chemicals) and 300 \u03bcM peptide (KKKISDELMDATFADQEAK). Assays were carried out at 25\u00b0 C. in the presence of 25 nM Plk1. An assay stock buffer solution was prepared containing all of the reagents listed above, with the exception of ATP and the test compound of interest. 30 \u03bcL of the stock solution was placed in a 96 well plate followed by addition of 2 \u03bcL of DMSO stock containing serial dilutions of the test compound (typically starting from a final concentration of 10 \u03bcM with 2-fold serial dilutions) in duplicate (final DMSO concentration 5%). The plate was pre-incubated for 10 minutes at 25\u00b0 C. and the reaction initiated by addition of 8 \u03bcL [\u03b3-33P]ATP (final concentration 100 \u03bcM).</p>The reaction was stopped after 90 minutes by the addition of 100 \u03bcL 0.14M phosphoric acid. A multiscreen phosphocellulose filter 96-well plate (Millipore, Cat no. MAPHNOB50) was pretreated with 100 \u03bcL 0.2M phosphoric acid prior to the addition of 125 \u03bcL of the stopped assay mixture. The plate was washed with 4\u00d7200 \u03bcL 0.2M phosphoric acid. After drying, 100 \u03bcL Optiphase \u2018SuperMix\u2019 liquid scintillation cocktail (Perkin Elmer) was added to the well prior to scintillation counting (1450 Microbeta Liquid Scintillation Counter, Wallac).</p>After removing mean background values for all of the data points, Ki(app) data were calculated from non-linear regression analysis of the initial rate data using the Prism software package (GraphPad Prism version 3.0cx for Macintosh, GraphPad Software, San Diego Calif., USA).</p>Plk2 Inhibition Assay:</p>Compounds were screened for their ability to inhibit Plk2 using a radioactive-phosphate incorporation assay. Assays were carried out in a mixture of 25 mM HEPES (pH 7.5), 10 mM MgCl<sub>2</sub>, 0.1% BSA, and 2 mM DTT. Final substrate concentrations were 200 \u03bcM [\u03b3-33P]ATP (57mCi 33P ATP/mmol ATP, Amersham Pharmacia Biotech/Sigma Chemicals) and 300 \u03bcM peptide (KKKISDELMDATFADQEAK). Assays were carried out at 25\u00b0 C. in the presence of 25 nM Plk2. An assay stock buffer solution was prepared containing all of the reagents listed above, with the exception of ATP and the test compound of interest. 30 \u03bcL of the stock solution was placed in a 96 well plate followed by addition of 2 \u03bcL of DMSO stock containing serial dilutions of the test compound (typically starting from a final concentration of 10 \u03bcM with 2-fold serial dilutions) in duplicate (final DMSO concentration 5%). The plate was pre-incubated for 10 minutes at 25\u00b0 C. and the reaction initiated by addition of 8 \u03bcL [\u03b3-33P]ATP (final concentration 200 \u03bcM).</p>The reaction was stopped after 90 minutes by the addition of 100 \u03bcL 0.14M phosphoric acid. A multiscreen phosphocellulose filter 96-well plate (Millipore, Cat no. MAPHNOB50) was pretreated with 100 \u03bcL 0.2M phosphoric acid prior to the addition of 125 \u03bcL of the stopped assay mixture. The plate was washed with 4\u00d7200 \u03bcL 0.2M phosphoric acid. After drying, 100 \u03bcL Optiphase \u2018SuperMix\u2019 liquid scintillation cocktail (Perkin Elmer) was added to the well prior to scintillation counting (1450 Microbeta Liquid Scintillation Counter, Wallac).</p>After removing mean background values for all of the data points, Ki(app) data were calculated from non-linear regression analysis of the initial rate data using the Prism software package (GraphPad Prism version 3.0cx for Macintosh, GraphPad Software, San Diego Calif., USA).</p>Plk3 Inhibition Assay:</p>Compounds were screened for their ability to inhibit Plk3 using a radioactive-phosphate incorporation assay. Assays were carried out in a mixture of 25 mM HEPES (pH 7.5), 10 mM MgCl<sub>2</sub>, and 1 mM DTT. Final substrate concentrations were 75 \u03bcM [\u03b3-33P]ATP (60mCi 33P ATP/mmol ATP, Amersham Pharmacia Biotech/Sigma Chemicals) and 10 \u03bcM peptide (SAM68 protein A332-443). Assays were carried out at 25\u00b0 C. in the presence of 5 nM Plk3 (S38-A340). An assay stock buffer solution was prepared containing all of the reagents listed above, with the exception of ATP and the test compound of interest. 30 \u03bcL of the stock solution was placed in a 96 well plate followed by addition of 2 \u03bcL of DMSO stock containing serial dilutions of the test compound (typically starting from a final concentration of 10 \u03bcM with 2-fold serial dilutions) in duplicate (final DMSO concentration 5%). The plate was pre-incubated for 10 minutes at 25\u00b0 C. and the reaction initiated by addition of 8 \u03bcL [\u03b3-33P]ATP (final concentration 75 \u03bcM).</p>The reaction was stopped after 60 minutes by the addition of 100 \u03bcL 0.14M phosphoric acid. A multiscreen phosphocellulose filter 96-well plate (Millipore, Cat no. MAPHNOB50) was pretreated with 100 \u03bcL 0.2M phosphoric acid prior to the addition of 125 \u03bcL of the stopped assay mixture. The plate was washed with 4\u00d7200 \u03bcL 0.2M phosphoric acid. After drying, 100 \u03bcL Optiphase \u2018SuperMix\u2019 liquid scintillation cocktail (Perkin Elmer) was added to the well prior to scintillation counting (1450 Microbeta Liquid Scintillation Counter, Wallac).</p>After removing mean background values for all of the data points, Ki(app) data were calculated from non-linear regression analysis of the initial rate data using the Prism software package (GraphPad Prism version 3.0cx for Macintosh, GraphPad Software, San Diego Calif., USA).</p>Plk4 Inhibition Assay:</p>Compounds are screened for their ability to inhibit Plk4 using a radioactive-phosphate incorporation assay. Assays are carried out in a mixture of 8 mM MOPS (pH 7.5), 10 mM MgCl<sub>2</sub>, 0.1% BSA and 2 mM DTT. Final substrate concentrations are 15 \u03bcM [\u03b3-33P]ATP (227mCi 33P ATP/mmol ATP, Amersham Pharmacia Biotech/Sigma Chemicals) and 300 \u03bcM peptide (KKKMDATFADQ). Assays are carried out at 25\u00b0 C. in the presence of 25 nM Plk4. An assay stock buffer solution is prepared containing all of the reagents listed above, with the exception of ATP and the test compound of interest. 30 \u03bcL of the stock solution is placed in a 96 well plate followed by addition of 2 \u03bcL of DMSO stock containing serial dilutions of the test compound (typically starting from a final concentration of 10 \u03bcM with 2-fold serial dilutions) in duplicate (final DMSO concentration 5%). The plate is pre-incubated for 10 minutes at 25\u00b0 C. and the reaction initiated by addition of 8 \u03bcL [\u03b3-33P]ATP (final concentration 15 \u03bcM).</p>The reaction is stopped after 180 minutes by the addition of 100 \u03bcL 0.14M phosphoric acid. A multiscreen phosphocellulose filter 96-well plate (Millipore, Cat no. MAPHNOB50) is pretreated with 100 \u03bcL 0.2M phosphoric acid prior to the addition of 125 \u03bcL of the stopped assay mixture. The plate is washed with 4\u00d7200 \u03bcL 0.2M phosphoric acid. After drying, 100 \u03bcL Optiphase \u2018SuperMix\u2019 liquid scintillation cocktail (Perkin Elmer) is added to the well prior to scintillation counting (1450 Microbeta Liquid Scintillation Counter, Wallac).</p>After removing mean background values for all of the data points, Ki(app) data are calculated from non-linear regression analysis of the initial rate data using the Prism software package (GraphPad Prism version 3.0cx for Macintosh, GraphPad Software, San Diego Calif., USA).</p>"
]